The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy.
OBJECTIVE
To evaluate the effect of hormonal manipulation on catheter dependency, the resolution of urinary symptomatology, and the need for postbrachytherapy transurethral/transincisional resection (TURP/TUIP).


METHODS
Seven hundred sixteen consecutive patients (median follow-up, 29 months) underwent brachytherapy for clinical T1b-T3a (1997 AJCC) prostate cancer from January 1998 through August 2002. Of the evaluated cohort, 400 patients were hormone naïve, 227 received short-course cytoreductive (< or = 6 months) hormonal therapy, and 89 received extended (>6 months) hormonal therapy. An alpha-blocker was initiated prior to implantation and continued at least until the International Prostate Symptom Score (I-PSS) returned to baseline levels. Evaluated parameters included age, T-stage, preimplant I-PSS, ultrasound volume, treatment planning volume, hormonal status, supplemental external beam radiation therapy (XRT), isotope, urethral dose, total implant activity, D90, and V100/150/200. Catheter dependency and the incidence of TURP/TUIP were also evaluated.


RESULTS
Six hundred fifty three patients (91.2%) had the urinary catheter permanently removed on day 0 with 15 patients (2.1%) requiring a catheter beyond 4 days. The I-PSS returned to within 1 point of the antecedent value at a median of 4 months. Sixteen patients (2.2%) underwent postimplant TURP/TUIP. A Cox regression indicated that preimplant I-PSS, supplemental XRT, planning target volume, hormonal therapy, and number of seeds were the strongest predictors for I-PSS resolution. Using all available data, the strongest predictors for I-PSS at 18 months following brachytherapy included variants of I-PSS, isotope, and days of catheter dependency. The maximum I-PSS, planning target volume, and XRT best predicted for prolonged (#10878;4 days) catheter dependency. The need for postimplant TURP/TUIP was most closely associated with days of catheter dependency and the maximum increase in I-PSS. However, when only data available prior to implantation was entered into the model, hormonal therapy predicted for postsurgical intervention.


CONCLUSIONS
In this retrospective evaluation, hormonal manipulation did not statistically impact short-term or prolonged urinary catheter dependency or I-PSS at 18 months, but did influence time to I-PSS normalization and the need for postbrachytherapy surgical intervention.
Merrick
Gregory S
GS
Schiffler Cancer Center, Wheeling Hospital, Wheeling, WV 26003-6300, USA. gmerrick@wheelinghospital.com
Butler
Wayne M
WM
Wallner
Kent E
KE
Murray
Brian
B
Allen
Zachariah
Z
Lief
Jonathan H
JH
Galbreath
Robert W
RW
D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001918:Brachytherapy / Q000009:adverse effects*; D015331:Cohort Studies; D003131:Combined Modality Therapy; D006801:Humans; D007457:Iodine Radioisotopes; D008297:Male; D010165:Palladium; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000532:radiotherapy* / Q000601:surgery; D011868:Radioisotopes; D012189:Retrospective Studies; D020728:Transurethral Resection of Prostate; D014546:Urinary Catheterization; D016055:Urinary Retention / Q000209:etiology* / Q000517:prevention & control*
D018931:Antineoplastic Agents, Hormonal; D007457:Iodine Radioisotopes; D011868:Radioisotopes; D010165:Palladium